Please use this identifier to cite or link to this item:
http://doi.org/10.25358/openscience-6898Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Moon, Euy Sung | - |
| dc.contributor.author | Elvas, Filipe | - |
| dc.contributor.author | Vliegen, Gwendolyn | - |
| dc.contributor.author | De Lombaerde, Stef | - |
| dc.contributor.author | Vangestel, Christel | - |
| dc.contributor.author | De Bruycker, Sven | - |
| dc.contributor.author | Bracke, An | - |
| dc.contributor.author | Eppard, Elisabeth | - |
| dc.contributor.author | Greifenstein, Lukas | - |
| dc.contributor.author | Klasen, Benedikt | - |
| dc.contributor.author | Kramer, Vasko | - |
| dc.contributor.author | Staelens, Steven | - |
| dc.contributor.author | De Meester, Ingrid | - |
| dc.contributor.author | Van der Veken, Pieter | - |
| dc.contributor.author | Rösch, Frank | - |
| dc.date.accessioned | 2022-04-22T08:32:11Z | - |
| dc.date.available | 2022-04-22T08:32:11Z | - |
| dc.date.issued | 2020 | - |
| dc.identifier.uri | https://openscience.ub.uni-mainz.de/handle/20.500.12030/6909 | - |
| dc.description.abstract | BACKGROUND Fibroblast activation protein (FAP) is a proline selective serine protease that is overexpressed in tumor stroma and in lesions of many other diseases that are characterized by tissue remodeling. In 2014, a most potent FAP-inhibitor (referred to as UAMC1110) with low nanomolar FAP-affinity and high selectivity toward related enzymes such as prolyl oligopeptidase (PREP) and the dipeptidyl-peptidases (DPPs): DPP4, DPP8/9 and DPP2 were developed. This inhibitor has been adopted recently by other groups to create radiopharmaceuticals by coupling bifunctional chelator-linker systems. Here, we report squaric acid (SA) containing bifunctional DATA5m and DOTA chelators based on UAMC1110 as pharmacophor. The novel radiopharmaceuticals DOTA.SA.FAPi and DATA5m.SA.FAPi with their non-radioactive derivatives were characterized for in vitro inhibitory efficiency to FAP and PREP, respectively and radiochemical investigated with gallium-68. Further, first proof-of-concept in vivo animal study followed by ex vivo biodistribution were determined with [68Ga]Ga-DOTA.SA.FAPi. RESULTS [68Ga]Ga-DOTA.SA.FAPi and [68Ga]Ga-DATA5m.SA.FAPi showed high complexation > 97% radiochemical yields after already 10 min and high stability over a period of 2 h. Affinity to FAP of DOTA.SA.FAPi and DATA5m.SA.FAPi and its natGa and natLu-labeled derivatives were excellent resulting in low nanomolar IC50 values of 0.7–1.4 nM. Additionally, all five compounds showed low affinity for the related protease PREP (high IC50 with 1.7–8.7 μM). First proof-of-principle in vivo PET-imaging animal studies of the [68Ga]Ga-DOTA.SA.FAPi precursor in a HT-29 human colorectal cancer xenograft mouse model indicated promising results with high accumulation in tumor (SUVmean of 0.75) and low background signal. Ex vivo biodistribution showed highest uptake in tumor (5.2%ID/g) at 60 min post injection with overall low uptake in healthy tissues. CONCLUSION In this work, novel PET radiotracers targeting fibroblast activation protein were synthesized and biochemically investigated. Critical substructures of the novel compounds are a squaramide linker unit derived from the basic motif of squaric acid, DOTA and DATA5m bifunctional chelators and a FAP-targeting moiety. In conclusion, these new FAP-ligands appear promising, both for further research and development as well as for first human application. | en_GB |
| dc.language.iso | eng | de |
| dc.rights | CC BY | * |
| dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | * |
| dc.subject.ddc | 540 Chemie | de_DE |
| dc.subject.ddc | 540 Chemistry and allied sciences | en_GB |
| dc.subject.ddc | 610 Medizin | de_DE |
| dc.subject.ddc | 610 Medical sciences | en_GB |
| dc.title | Targeting fibroblast activation protein (FAP) : next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA5m chelators | en_GB |
| dc.type | Zeitschriftenaufsatz | de |
| dc.identifier.doi | http://doi.org/10.25358/openscience-6898 | - |
| jgu.type.dinitype | article | en_GB |
| jgu.type.version | Published version | de |
| jgu.type.resource | Text | de |
| jgu.organisation.department | FB 09 Chemie, Pharmazie u. Geowissensch. | de |
| jgu.organisation.number | 7950 | - |
| jgu.organisation.name | Johannes Gutenberg-Universität Mainz | - |
| jgu.rights.accessrights | openAccess | - |
| jgu.journal.title | EJNMMI radiopharmacy and chemistry | de |
| jgu.journal.volume | 5 | de |
| jgu.pages.alternative | 19 | de |
| jgu.publisher.year | 2020 | - |
| jgu.publisher.name | Springer International Publishing | de |
| jgu.publisher.place | Cham, Switzerland | de |
| jgu.publisher.issn | 2365-421X | de |
| jgu.organisation.place | Mainz | - |
| jgu.subject.ddccode | 540 | de |
| jgu.subject.ddccode | 610 | de |
| jgu.publisher.doi | 10.1186/s41181-020-00102-z | de |
| jgu.organisation.ror | https://ror.org/023b0x485 | |
| Appears in collections: | JGU-Publikationen | |
Files in This Item:
| File | Description | Size | Format | ||
|---|---|---|---|---|---|
 | targeting_fibroblast_activati-20220422101605679.pdf | 1.12 MB | Adobe PDF | View/Open |